Skip to main content

Table 5 Bleeding and thromboembolic events in the interventional and observational cohorts

From: Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19

 

Interventional cohort

Observational cohort

P-value

N

n (%)

N

n (%)

Bleeding at 30 days

93

5 (5.4%)

186

1 (0.5%)

0.02

Minor 4 (80%)

 

Minor 1 (100%)

 

Major 1 (20%)

 

Major 0 (0%)

0.33

Thromboembolic events at 30 days

92

0 (0.0%)

186

4 (2.2%)

0.31

Bleeding at 90 days

93

2 (2.2%)

184

3 (1.6%)

1.00

Thromboembolic events at 90 days

93

3 (3.2%)

184

0 (0.0%)

0.04